These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20433045)

  • 41. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 42. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug and device litigation in the 21st century.
    Svitak LS; Goss PJ
    Spec Law Dig Health Care Law; 2001 Nov; (271):9-36. PubMed ID: 11802352
    [No Abstract]   [Full Text] [Related]  

  • 44. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 45. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
    O'Reilly J; Dalal A
    Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 47. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Duty to Warn.
    Clark JR
    Air Med J; 2018; 37(4):229-230. PubMed ID: 29935699
    [No Abstract]   [Full Text] [Related]  

  • 49. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 50. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 51. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 52. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 53. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 54. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 55. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
    Levy E
    Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
    [No Abstract]   [Full Text] [Related]  

  • 57. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

  • 58. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 59. Implants with flaws: disclosure and delay.
    Meier B
    N Y Times Web; 2005 Jun; ():C1, C3. PubMed ID: 15966120
    [No Abstract]   [Full Text] [Related]  

  • 60. The Supreme Court rules: the FDA and tobacco regulation.
    Benjamin GC
    Physician Exec; 2000; 26(4):76-7. PubMed ID: 11183241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.